• Outstanding efficiency
  
• No modification of cellular metabolism
  
• No acquired resistance

The potent activity of Plasmocin� is due to two unique bactericidal components. The first component acts on the protein synthesis machinery by interfering with ribosome translation. The second acts on the DNA replication by interfering with the replication fork. These two specific and separate targets are found only in Mycoplasma and many other bacteria and are completely absent in eukaryotic cells.

In contrast to other anti-Mycoplasma compounds, Plasmocin� is active both on free Mycoplasma as well as intracellular forms because one antibiotic comprising Plasmocin� is actively transported into mammalian cells. This benefit insures that following treatment with Plasmocin�, a cell culture is not reinfected by Mycoplasma released from intracellular compartments of infected cells.

In all animal cell lines tested to date, even at five times the working concentration, no apparent adverse effect on cellular metabolism is observed.

No resistance in liquid cultures has ever been identified in repeated experiments attempting to measure the mutation rate. Therefore, development of resistant Mycoplasma strains is virtually eliminated.
Also active against bacteria contaminations Plasmocin� is also active at low concentrations on a broad range of gram positive and gram negative bacteria that are otherwise resistant to the mixture of streptomycin and penicillin, and exhibits no toxicity in eukaryotic cells. 

• For Mycoplasma elimination: use Plasmocin� at 25�g/ml for two weeks in the infected culture. A 1000X solution specific for treatment (ant-mpt) is provided.

• To prevent Mycoplasma infection use Plasmocin� 2.5�g/ml on a regular basis in cell culture. A 1000X solution specific for prophylactic use (ant-mpp) is provided.